These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20202650)

  • 1. Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later.
    Scott TF; Schramke CJ
    J Neurol Sci; 2010 May; 292(1-2):52-6. PubMed ID: 20202650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors of multiple sclerosis in Lebanon.
    Yamout B; Itani S; Arabi A; Hamzeh D; Yaghi S
    Int J Neurosci; 2010 Mar; 120(3):206-10. PubMed ID: 20374088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is late-onset multiple sclerosis associated with a worse outcome?
    Tremlett H; Devonshire V
    Neurology; 2006 Sep; 67(6):954-9. PubMed ID: 17000960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population.
    El-Salem K; Khader Y
    Clin Neurol Neurosurg; 2007 Jan; 109(1):32-7. PubMed ID: 16870328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical course of multiple sclerosis patients in Hong Kong.
    Lau KK; Wong WW; Sheng B; Yu IT; Fung BH; Li HL; Ma KF; Wong LK; Li PC
    J Neurol Sci; 2008 May; 268(1-2):78-82. PubMed ID: 18068191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disability progression in multiple sclerosis is slower than previously reported.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with the risk of secondary progression in multiple sclerosis.
    Koch M; Uyttenboogaart M; van Harten A; De Keyser J
    Mult Scler; 2008 Jul; 14(6):799-803. PubMed ID: 18573840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Late onset multiple sclerosis].
    Delalande S; De Seze J; Ferriby D; Stojkovic T; Vermersch P
    Rev Neurol (Paris); 2002 Nov; 158(11):1082-7. PubMed ID: 12451340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study.
    Leone MA; Bonissoni S; Collimedaglia L; Tesser F; Calzoni S; Stecco A; Naldi P; Monaco F
    Mult Scler; 2008 May; 14(4):485-93. PubMed ID: 18208889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyotrophic lateral sclerosis: prognostic indicators of survival.
    Mandrioli J; Faglioni P; Nichelli P; Sola P
    Amyotroph Lateral Scler; 2006 Dec; 7(4):211-20. PubMed ID: 17127559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benign multiple sclerosis in Crete.
    Mastorodemos V; Nikolakaki H; Tzagournissakis M; Kotzamani D; Panou T; Spanaki C; Klados G; Maris T; Kontolaimaki E; Psaroudaki K; Chlouverakis G; Georgakakis G; Plaitakis A
    Mult Scler; 2010 Jun; 16(6):701-6. PubMed ID: 20237192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France.
    Lebrun C; Debouverie M; Jeannin S; Pittion-Vouyovitch S; Bayreuther C; Berthier F
    Mult Scler; 2008 Aug; 14(7):933-9. PubMed ID: 18573824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic indicators for long-term disability in multiple sclerosis patients.
    Damasceno A; Von Glehn F; Brandão CO; Damasceno BP; Cendes F
    J Neurol Sci; 2013 Jan; 324(1-2):29-33. PubMed ID: 23073568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients.
    Smestad C; Sandvik L; Celius EG
    Mult Scler; 2009 Nov; 15(11):1263-70. PubMed ID: 19812114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.